Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine - Advisory Committee on Immunization Practices, 2016

• Type of Material: Article
• Authors: Monica E. Patton, Emory University; David S Stephens, Emory University; Kelly Moore, Emory University; Jessica R. MacNeil, Centers for Disease Control and Prevention
• Language: English
• Date: 2017-05-19
• Publisher: Centers for Disease Control and Prevention
• Publication Version: Final Published Version
• Copyright Statement: © 2017, Department of Health and Human Services. All rights reserved.
• License: Creative Commons Creative Commons CC0 1.0 Universal
• Final Published Version (URL): http://dx.doi.org/10.15585/mmwr.mm6619a6
• Title of Journal or Parent Work: MMWR. Morbidity and mortality weekly report
• ISSN: 0149-2195
• Volume: 66
• Issue: 19
• Start Page: 509
• End Page: 513
• Keywords: Life Sciences & Biomedicine; Science & Technology; Public, Environmental & Occupational Health; DISEASE
• Research Categories: Health Sciences, Immunology; Health Sciences, General

Abstract

What is currently recommended? Two serogroup B meningococcal (MenB) vaccines are currently licensed for use among persons aged 10-25 years in the United States: MenB-FHbp (Trumenba) and MenB-4C (Bexsero). The Advisory Committee on Immunization Practices (ACIP) currently recommends routine use of MenB vaccines among persons aged ≥10 years who are at increased risk for serogroup B meningococcal disease (Category A recommendation), including persons who have persistent complement component deficiencies; persons who have anatomic or functional asplenia; microbiologists who routinely are exposed to isolates of Neisseria meningitidis; and persons identified to be at increased risk because of a serogroup B meningococcal disease outbreak. Adolescents and young adults aged 16-23 years may also be vaccinated with MenB vaccines to provide short-term protection against most strains of serogroup B meningococcal disease (Category B recommendation). Consistent with the original Food and Drug Administration (FDA) licensure for the MenB vaccines, ACIP recommended either a 3-dose series of MenB-FHbp or a 2-dose series of MenB-4C. Either MenB vaccine can be used when indicated; however, they are not interchangeable, and the same product must be used for all doses. Why are the recommendations being modified now? Changes to the dosage and administration of MenB-FHbp were approved by FDA to include both a 3-dose series (administered at 0, 1-2, and 6 months) and a 2-dose series (administered at 0 and 6 months). What are the new recommendations? These updated recommendations are regarding use of the 2- and 3-dose schedules of MenB-FHbp vaccine (Trumenba). For persons at increased risk for meningococcal disease and for use during serogroup B meningococcal disease outbreaks, ACIP recommends that 3 doses of MenB-FHbp be administered at 0, 1-2, and 6 months. When given to healthy adolescents who are not at increased risk for meningococcal disease, ACIP recommends that 2 doses of MenB-FHbp should be administered at 0 and 6 months. Recommendations regarding use of MenB-4C vaccine (Bexsero) are unchanged. Either MenB vaccine can be used when indicated; however, they are not interchangeable, and the same product must be used for all doses in a series.